<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">25879104</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1469-493X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>1</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2015</Year>
              <Month>Jan</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Cochrane database of systematic reviews</Title>
          <ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide for neuropathic pain in adults.</ArticleTitle>
        <Pagination>
          <StartPage>CD011241</StartPage>
          <MedlinePgn>CD011241</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">CD011241</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD011241.pub2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. The efficacy of zonisamide for the relief of neuropathic pain has not previously been reviewed.</AbstractText>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the analgesic efficacy and associated adverse events of zonisamide for chronic neuropathic pain in adults.</AbstractText>
          <AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (via CRSO), MEDLINE, EMBASE, and two clinical trials databases (ClinicalTrials.gov. and the World Health Organisation Clinical Trials Registry Platform) to 1 August 2014, together with reference lists of retrieved papers and reviews.</AbstractText>
          <AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">We included randomised, double-blind studies of at least two weeks' duration comparing zonisamide with placebo or another active treatment in chronic neuropathic pain. Participants were adults aged 18 and over. We included only full journal publication articles and clinical trial summaries.</AbstractText>
          <AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently extracted efficacy and adverse event data, and examined issues of study quality. We considered the evidence using three tiers. First tier evidence derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts; at least 200 participants in the comparison, 8 to 12 weeks duration, parallel design); second tier evidence derived from data that failed to meet one or more of these criteria and were considered at some risk of bias but with adequate numbers in the comparison; and third tier evidence derived from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both.We planned to calculate risk ratio (RR) and numbers needed to treat (NNT) and harm (NNH) for one additional event using standard methods expected by The Cochrane Collaboration.</AbstractText>
          <AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included a single study treating 25 participants (13 zonisamide, 12 placebo) with painful diabetic neuropathy over 12 weeks. No first or second tier evidence was available for any outcome. The small size of the study and potential major bias due to a high proportion of early study withdrawals with zonisamide precluded any conclusions being drawn. There were two serious adverse events (one death) in zonisamide-treated participants, which were apparently not related to treatment.</AbstractText>
          <AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">The review found a lack of evidence suggesting that zonisamide provides pain relief in any neuropathic pain condition. Effective medicines with much greater supportive evidence are available.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Moore</LastName>
            <ForeName>R Andrew</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Oxford, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiffen</LastName>
            <ForeName>Philip J</ForeName>
            <Initials>PJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Derry</LastName>
            <ForeName>Sheena</ForeName>
            <Initials>S</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lunn</LastName>
            <ForeName>Michael P T</ForeName>
            <Initials>MP</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>13/89/29</GrantID>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>MR/K000608/1</GrantID>
            <Acronym>MRC_</Acronym>
            <Agency>Medical Research Council</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cochrane Database Syst Rev</MedlineTA>
        <NlmUniqueID>100909747</NlmUniqueID>
        <ISSNLinking>1361-6137</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="UpdateOf">
          <RefSource>doi: 10.1002/14651858.CD011241</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003929" MajorTopicYN="N">Diabetic Neuropathies</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>SD has no conflicts relating to this review or any similar product. ML has no conflicts relating to this review or any similar product. PW has no conflicts relating to this review or any similar product. RAM has no conflicts relating to this review or any similar product. For transparency we have received research support from charities, government, and industry sources at various times, but none relate to this review. We are funded by the NIHR for work on a series of reviews informing the unmet need of chronic pain and providing the evidence for treatments of pain.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>4</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">25879104</ArticleId>
        <ArticleId IdType="pmc">PMC6485502</ArticleId>
        <ArticleId IdType="doi">10.1002/14651858.CD011241.pub2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References to studies included in this review</Title>
        <Reference>
          <Citation>Atli A, 
Dogra S. 
Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double‐blind, placebo‐controlled pilot study. 
Pain Medicine 2005;6(3):225‐34. 
[DOI: 10.1111/j.1526-4637.2005.05035.x]</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1526-4637.2005.05035.x</ArticleId>
            <ArticleId IdType="pubmed">15972086</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
      <ReferenceList>
        <Title>Additional references</Title>
        <Reference>
          <Citation>Apkarian AV, 
Hashmi JA, 
Baliki MN. 
Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. 
Pain 2011;152(3 Suppl):S49‐64. 
[DOI: 10.1016/j.pain.2010.11.010]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.11.010</ArticleId>
            <ArticleId IdType="pmc">PMC3045648</ArticleId>
            <ArticleId IdType="pubmed">21146929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cochrane Pain, 
Palliative and Supportive Care Group. 
PaPaS Author and Referee Guidance. 
http://papas.cochrane.org/papas‐documents (accessed 1 August 2014)2012.
</Citation>
        </Reference>
        <Reference>
          <Citation>Baron R, 
Binder A, 
Wasner G. 
Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. 
Lancet Neurology 2010;9(8):807‐19. 
[DOI: 10.1016/S1474-4422(10)70143-5]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(10)70143-5</ArticleId>
            <ArticleId IdType="pubmed">20650402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baron R, 
Wasner G, 
Binder A. 
Chronic pain: genes, plasticity, and phenotypes. 
Lancet Neurology 2012;11(1):19‐21. 
[DOI: 10.1016/S1474-4422(11)70281-2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(11)70281-2</ArticleId>
            <ArticleId IdType="pubmed">22172618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bektas N, 
Arslan R, 
Ozturk Y. 
Zonisamide: Antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy. 
Life Sciences 2014;95(1):9‐13. 
[DOI: 10.1016/j.lfs.2013.12.012]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2013.12.012</ArticleId>
            <ArticleId IdType="pubmed">24361360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouhassira D, 
Lantéri‐Minet M, 
Attal N, 
Laurent B, 
Touboul C. 
Prevalence of chronic pain with neuropathic characteristics in the general population. 
Pain 2008;136(3):380‐7. 
[DOI: 10.1016/j.pain.2007.08.013]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2007.08.013</ArticleId>
            <ArticleId IdType="pubmed">17888574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, 
Ben‐Menachem E, 
Chouette I, 
Giorgi L. 
Zonisamide: its pharmacology, efficacy and safety in clinical trials. 
Acta Neurologica Scandinavia 2012;126 (Suppl 194):19‐28. 
[DOI: 10.1111/ane.12016]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ane.12016</ArticleId>
            <ArticleId IdType="pubmed">23106522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derry S, 
Moore RA. 
Topical capsaicin (low concentration) for chronic neuropathic pain in adults. 
Cochrane Database of Systematic Reviews 2012, Issue 9. 
[DOI: 10.1002/14651858.CD010111]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD010111</ArticleId>
            <ArticleId IdType="pmc">PMC6540838</ArticleId>
            <ArticleId IdType="pubmed">22972149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derry S, 
Sven‐Rice A, 
Cole P, 
Tan T, 
Moore RA. 
Topical capsaicin (high concentration) for chronic neuropathic pain in adults. 
Cochrane Database of Systematic Reviews 2013, Issue 2. 
[DOI: 10.1002/14651858.CD007393.pub3]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD007393.pub3</ArticleId>
            <ArticleId IdType="pubmed">23450576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derry S, 
Wiffen PJ, 
Moore RA, 
Quinlan J. 
Topical lidocaine for neuropathic pain in adults. 
Cochrane Database of Systematic Reviews 2014, Issue 7. 
[DOI: 10.1002/14651858.CD010958.pub2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD010958.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6540846</ArticleId>
            <ArticleId IdType="pubmed">25058164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dworkin RH, 
Turk DC, 
Wyrwich KW, 
Beaton D, 
Cleeland CS, 
Farrar JT, 
et al. 
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. 
Journal of Pain 2008;9(2):105‐21. 
[DOI: 10.1016/j.jpain.2007.09.005]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpain.2007.09.005</ArticleId>
            <ArticleId IdType="pubmed">18055266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gustorff B, 
Dorner T, 
Likar R, 
Grisold W, 
Lawrence K, 
Schwarz F, 
et al. 
Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. 
Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. 
[DOI: 10.1111/j.1399-6576.2007.01486.x]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1399-6576.2007.01486.x</ArticleId>
            <ArticleId IdType="pubmed">17976220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall GC, 
Carroll D, 
McQuay HJ. 
Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. 
BMC Family Practice 2008;9:26. 
[DOI: 10.1186/1471-2296-9-26]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2296-9-26</ArticleId>
            <ArticleId IdType="pmc">PMC2413228</ArticleId>
            <ArticleId IdType="pubmed">18460194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hasegawa H. 
Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. 
Current Medical Research and Opinion 2004;20(5):577‐80. 
[DOI: 10.1185/030079904125003313]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/030079904125003313</ArticleId>
            <ArticleId IdType="pubmed">15140322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, 
Green S (editors). 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. 
Available from www.cochrane‐handbook.org.
</Citation>
        </Reference>
        <Reference>
          <Citation>Jadad AR, 
Moore RA, 
Carroll D, 
Jenkinson C, 
Reynolds DJ, 
Gavaghan DJ, 
et al. 
Assessing the quality of reports of randomized clinical trials: is blinding necessary?. 
Controlled Clinical Trials 1996;17(1):1‐12. 
[DOI: 10.1016/0197-2456(95)00134-4]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId>
            <ArticleId IdType="pubmed">8721797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jensen TS, 
Baron R, 
Haanpää M, 
Kalso E, 
Loeser JD, 
Rice AS, 
et al. 
A new definition of neuropathic pain. 
Pain 2011;152(10):2204‐5. 
[DOI: 10.1016/j.pain.2011.06.017]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2011.06.017</ArticleId>
            <ArticleId IdType="pubmed">21764514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalso E, 
Aldington DJ, 
Moore RA. 
Drugs for neuropathic pain. 
BMJ 2013;347:f7339. 
[DOI: 10.1136/bmj.f7339]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.f7339</ArticleId>
            <ArticleId IdType="pubmed">24355386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katusic S, 
Williams DB, 
Beard CM, 
Bergstralh EJ, 
Kurland LT. 
Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945‐1984. 
Neuroepidemiology 1991;10(5‐6):276‐81.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1798430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koopman JS, 
Dieleman JP, 
Huygen FJ, 
Mos M, 
Martin CG, 
Sturkenboom MC. 
Incidence of facial pain in the general population. 
Pain 2009;147(1‐3):122‐7. 
[DOI: 10.1016/j.pain.2009.08.023]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2009.08.023</ArticleId>
            <ArticleId IdType="pubmed">19783099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krusz JC. 
Treatment of chronic pain with zonisamide. 
Pain Practice 2003;3(4):317‐20. 
[DOI: 10.1111/j.1530-7085.2003.03035.x]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1530-7085.2003.03035.x</ArticleId>
            <ArticleId IdType="pubmed">17166127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L'Abbé KA, 
Detsky AS, 
O'Rourke K. 
Meta‐analysis in clinical research. 
Annals of Internal Medicine 1987;107:224‐33.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3300460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lunn MP, 
Hughes RA, 
Wiffen PJ. 
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. 
Cochrane Database of Systematic Reviews 2014, Issue 1. 
[DOI: 10.1002/14651858.CD007115.pub3]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD007115.pub3</ArticleId>
            <ArticleId IdType="pubmed">24385423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McQuay H, 
Moore R. 
An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. 
[ISBN: 0‐19‐263048‐2]
</Citation>
        </Reference>
        <Reference>
          <Citation>McQuay HJ, 
Smith LA, 
Moore RA. 
Chronic pain. 
In: Stevens A, 
Raftery J, 
Mant J, 
Simpson S editor(s). 
Health Care Needs Assessment. 3rd Edition. Oxford: Radcliffe Publishing, 2007. 
[ISBN: 978‐1‐84619‐063‐6]
</Citation>
        </Reference>
        <Reference>
          <Citation>Mohammadianinejad SE, 
Abbasi V, 
Sajedi SA, 
Majdinasab N, 
Abdollahi F, 
Hajmanouchehri R, 
Faraji A. 
Zonisamide versus topiramate in migraine prophylaxis: a double‐blind randomized clinical trial. 
Clinical Neuropharmacology 2011;34(4):174‐7. 
[DOI: 10.1097/WNF.0b013e318225140c]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNF.0b013e318225140c</ArticleId>
            <ArticleId IdType="pubmed">21738025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moisset X, 
Bouhassira D. 
Brain imaging of neuropathic pain. 
Neuroimaging 2007;37(Suppl 1):S80‐8. 
[DOI: 10.1016/j.neuroimage.2007.03.054]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuroimage.2007.03.054</ArticleId>
            <ArticleId IdType="pubmed">17512757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Gavaghan D, 
Tramèr MR, 
Collins SL, 
McQuay HJ. 
Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. 
Pain 1998;78(3):209‐16. 
[DOI: 10.1016/S0304-3959(98)00140-7]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0304-3959(98)00140-7</ArticleId>
            <ArticleId IdType="pubmed">9870574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Barden J, 
Derry S, 
McQuay HJ. 
Managing potential publication bias. 
In: McQuay HJ, 
Kalso E, 
Moore RA editor(s). 
Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. 
[ISBN: 978–0–931092–69–5]
</Citation>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Wiffen PJ, 
Derry S, 
McQuay HJ. 
Pregabalin for acute and chronic pain in adults. 
Cochrane Database of Systematic Reviews 2009, Issue 3. 
[DOI: 10.1002/14651858.CD007076.pub2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD007076.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC4167351</ArticleId>
            <ArticleId IdType="pubmed">19588419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Eccleston C, 
Derry S, 
Wiffen P, 
Bell RF, 
Straube S, 
et al. 
"Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. 
Pain 2010;150(3):386‐9. 
[DOI: 10.1016/j.pain.2010.05.011]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.05.011</ArticleId>
            <ArticleId IdType="pubmed">20627575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Derry S, 
McQuay HJ. 
Topical review: chronic low back pain analgesic studies ‐ a methodological minefield. 
Pain 2010;149(3):431‐4. 
[DOI: 10.1016/j.pain.2010.02.032]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.02.032</ArticleId>
            <ArticleId IdType="pubmed">20304558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Moore OA, 
Derry S, 
Peloso PM, 
Gammaitoni AR, 
Wang H. 
Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. 
Annals of the Rheumatic Diseases 2010;69(2):374‐9. 
[DOI: 10.1136/ard.2009.107805]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/ard.2009.107805</ArticleId>
            <ArticleId IdType="pmc">PMC2800200</ArticleId>
            <ArticleId IdType="pubmed">19364730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Paine J, 
Phillips CJ, 
Derry S, 
McQuay HJ. 
Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. 
Pain 2010;149(2):360‐4. 
[DOI: 10.1016/j.pain.2010.02.039]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.02.039</ArticleId>
            <ArticleId IdType="pubmed">20347225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Smugar SS, 
Wang H, 
Peloso PM, 
Gammaitoni A. 
Numbers‐needed‐to‐treat analyses ‐ do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. 
Pain 2010;151(3):592‐7. 
[DOI: 10.1016/j.pain.2010.07.013]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.07.013</ArticleId>
            <ArticleId IdType="pubmed">20810214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Paine J, 
Derry S, 
McQuay HJ. 
Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. 
Pain 2011;152(5):982‐9. 
[DOI: 10.1016/j.pain.2010.11.030]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2010.11.030</ArticleId>
            <ArticleId IdType="pubmed">21414722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Mhuircheartaigh RJ, 
Derry S, 
McQuay HJ. 
Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. 
European Journal of Anaesthesiology 2011;28(6):427‐32. 
[DOI: 10.1097/EJA.0b013e328343c569]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/EJA.0b013e328343c569</ArticleId>
            <ArticleId IdType="pubmed">21445017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Derry S, 
Aldington D, 
Cole P, 
Wiffen PJ. 
Amitriptyline for neuropathic pain and fibromyalgia in adults. 
Cochrane Database of Systematic Reviews 2012, Issue 12. 
[DOI: 10.1002/14651858.CD008242.pub2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD008242.pub2</ArticleId>
            <ArticleId IdType="pubmed">23235657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Eccleston C, 
Derry S, 
Aldington D, 
Wiffen P, 
et al. 
Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. 
Pain 2012;153(2):265‐8. 
[DOI: 10.1016/j.pain.2011.10.004]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2011.10.004</ArticleId>
            <ArticleId IdType="pubmed">22055553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Straube S, 
Aldington D. 
Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. 
Anaesthesia 2013;68(4):400‐12. 
[DOI: 10.1111/anae.12148]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/anae.12148</ArticleId>
            <ArticleId IdType="pubmed">23347230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore A, 
Derry S, 
Eccleston C, 
Kalso E. 
Expect analgesic failure; pursue analgesic success. 
BMJ 2013;346:f2690. 
[DOI: 10.1136/bmj.f2690]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.f2690</ArticleId>
            <ArticleId IdType="pubmed">23645858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Derry S, 
Taylor RS, 
Straube S, 
Phillips CJ. 
The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. 
Pain Practice 2014;14(1):79‐94. 
[DOI: 10.1111/papr.12050]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/papr.12050</ArticleId>
            <ArticleId IdType="pubmed">23464879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Cai N, 
Skljarevski V, 
Tölle TR. 
Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. 
European Journal of Pain 2014;18(1):65‐75. 
[DOI: 10.1002/j.1532-2149.2013.00341.x]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/j.1532-2149.2013.00341.x</ArticleId>
            <ArticleId IdType="pmc">PMC4302330</ArticleId>
            <ArticleId IdType="pubmed">23733529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, 
Wiffen PJ, 
Derry S, 
Toelle T, 
Rice AS. 
Gabapentin for chronic neuropathic pain and fibromyalgia in adults. 
Cochrane Database of Systematic Reviews 2014, Issue 4. 
[DOI: 10.1002/14651858.CD007938.pub3]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD007938.pub3</ArticleId>
            <ArticleId IdType="pmc">PMC6464253</ArticleId>
            <ArticleId IdType="pubmed">24771480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Care Excellence. 
Neuropathic pain – pharmacological management: The pharmacological management of neuropathic pain in adults in non‐specialist settings. 
http://www.nice.org.uk/guidance/CG173 (accessed 1 August 2014)2013. 
[www.nice.org.uk/nicemedia/live/13566/64189/64189.pdf ]
</Citation>
        </Reference>
        <Reference>
          <Citation>O'Brien EM, 
Staud RM, 
Hassinger AD, 
McCulloch RC, 
Craggs JG, 
Atchison JW, 
et al. 
Patient‐centered perspective on treatment outcomes in chronic pain. 
Pain Medicine 2010;11(1):6‐15. 
[DOI: 10.1111/j.1526-4637.2009.00685.x]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1526-4637.2009.00685.x</ArticleId>
            <ArticleId IdType="pubmed">19732374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Connor AB, 
Dworkin RH. 
Treatment of neuropathic pain: an overview of recent guidelines. 
American Journal of Medicine 2009;122(10 Suppl):S22‐32. 
[DOI: 10.1016/j.amjmed.2009.04.007]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2009.04.007</ArticleId>
            <ArticleId IdType="pubmed">19801049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rappaport ZH, 
Devor M. 
Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. 
Pain 1994;56(2):127‐38. 
[DOI: 10.1016/0304-3959(94)90086-8]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0304-3959(94)90086-8</ArticleId>
            <ArticleId IdType="pubmed">8008402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Nordic Cochrane Centre, The Cochrane Collaboration. 
Review Manager (RevMan). 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
</Citation>
        </Reference>
        <Reference>
          <Citation>Sakaue A, 
Honda M, 
Tanabe M, 
Ono H. 
Antinociceptive effects of sodium channel‐blocking agents on acute pain in mice. 
Journal of Pharmacological Sciences 2004;95(2):181‐8.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15215642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soni A, 
Batra R, 
Gwilym S, 
Spector T, 
Hart D, 
Arden N, 
et al. 
Neuropathic features of joint pain: a community‐based study. 
Arthritis and Rheumatism 2013;65(7):1942‐9. 
[DOI: 10.1002/art.37962]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.37962</ArticleId>
            <ArticleId IdType="pmc">PMC3701477</ArticleId>
            <ArticleId IdType="pubmed">23553508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straube S, 
Derry S, 
McQuay HJ, 
Moore RA. 
Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. 
British Journal of Clinical Pharmacology 2008;66(2):266‐75. 
[DOI: 10.1111/j.1365-2125.2008.03200.x]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2008.03200.x</ArticleId>
            <ArticleId IdType="pmc">PMC2492925</ArticleId>
            <ArticleId IdType="pubmed">18489611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straube S, 
Derry S, 
Moore RA, 
Paine J, 
McQuay HJ. 
Pregabalin in fibromyalgia‐responder analysis from individual patient data. 
BMC Musculoskeletal Disorders 2010;11:150. 
[DOI: 10.1186/1471-2474-11-150]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2474-11-150</ArticleId>
            <ArticleId IdType="pmc">PMC2906437</ArticleId>
            <ArticleId IdType="pubmed">20602781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, 
Hashimoto K, 
Tsuji S. 
Successful use of zonisamide for central poststroke pain. 
Journal of Pain 2004;5(3):192‐4. 
[DOI: 10.1016/j.jpain.2004.01.002]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpain.2004.01.002</ArticleId>
            <ArticleId IdType="pubmed">15106132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanabe M, 
Murakami T, 
Ono H. 
Zonisamide suppresses pain symptoms of formalin‐induced inflammatory and streptozotocin‐induced diabetic neuropathy. 
Journal of Pharmaceutical Sciences 2008;107(2):213‐20.
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18544896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrance N, 
Smith BH, 
Bennett MI, 
Lee AJ. 
The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. 
Journal of Pain 2006;7(4):281‐9. 
[DOI: 10.1016/j.jpain.2005.11.008]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpain.2005.11.008</ArticleId>
            <ArticleId IdType="pubmed">16618472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracey I. 
Can neuroimaging studies identify pain endophenotypes in humans?. 
Nature Reviews Neurology 2011;7(3):173‐81. 
[DOI: 10.1038/nrneurol.2011.4]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrneurol.2011.4</ArticleId>
            <ArticleId IdType="pubmed">21304481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treede RD, 
Jensen TS, 
Campbell JN, 
Cruccu G, 
Dostrovsky JO, 
Griffin JW, 
et al. 
Neuropathic pain: redefinition and a grading system for clinical and research purposes. 
Neurology 2008;70(18):1630‐5. 
[DOI: 10.1212/01.wnl.0000282763.29778.59]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000282763.29778.59</ArticleId>
            <ArticleId IdType="pubmed">18003941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hecke O, 
Austin SK, 
Khan RA, 
Smith BH, 
Torrance N. 
Neuropathic pain in the general population: a systematic review of epidemiological studies. 
Pain 2014;155(4):654‐62. 
[DOI: 10.1016/j.pain.2013.11.013]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pain.2013.11.013</ArticleId>
            <ArticleId IdType="pubmed">24291734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hehn CA, 
Baron R, 
Woolf CJ. 
Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. 
Neuron 2012;73(4):638‐52. 
[DOI: 10.1016/j.neuron.2012.02.008]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2012.02.008</ArticleId>
            <ArticleId IdType="pmc">PMC3319438</ArticleId>
            <ArticleId IdType="pubmed">22365541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vos T, 
Flaxman AD, 
Naghavi M, 
Lozano R, 
Michaud C, 
Ezzati M, 
et al. 
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012;380(9859):2163‐96. 
[DOI: 10.1016/S0140-6736(12)61729-2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(12)61729-2</ArticleId>
            <ArticleId IdType="pmc">PMC6350784</ArticleId>
            <ArticleId IdType="pubmed">23245607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiffen PJ, 
Derry S, 
Moore RA, 
Aldington D, 
Cole P, 
Rice ASC, 
et al. 
Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. 
Cochrane Database of Systematic Reviews 2013, Issue 11. 
[DOI: 10.1002/14651858.CD010567.pub2]
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD010567.pub2</ArticleId>
            <ArticleId IdType="pmc">PMC6469538</ArticleId>
            <ArticleId IdType="pubmed">24217986</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
